5 Topic Commentaries

This Week’s Biopharma News: Big Moves in Bispecifics

• 

  Alison M. Schram, MD

  Medical Oncology (Gynecologic Oncology)

  •

  Memorial Sloan Kettering Cancer Center

  “These results are particularly exciting because NRG1+ lung cancers typically do not respond to standard chemotherapy or immunotherapy and there are no approved targeted treatments for this patient population,”

  Source
• 

  Rafael Fonseca, MD

  Hematology/Oncology (Multiple Myeloma)

  •

  Mayo Clinic Cancer Center

  “At the ASH meeting, everyone agreed that the bispecific antibody presentations in multiple myeloma — of which this was one of two — were deemed the most striking,”

  Source
• 

  Richard Pazdur, MD

  Medical Oncology / Regulatory Science

  •

  U.S. Food and Drug Administration

  “This is the first FDA-approved treatment for patients with MRD-positive ALL,”

  Source
• 

  Alexander M. Lesokhin, MD

  Hematologic Oncology (Multiple Myeloma)

  •

  Memorial Sloan Kettering Cancer Center

  “Elranatamab appears to work on patients whether or not they have been previously treated with BCMA-directed therapies, including CAR T therapy,”

  Source
• 

  Saad Z. Usmani, MD, MBA

  Hematologic Oncology (Multiple Myeloma)

  •

  Memorial Sloan Kettering Cancer Center

  “It’s a major advance to have another therapy that we can give to patients right away when other treatments stop working,”

  Source